Brontictuzumab

Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma[1][2][3].

Product Specifications

CAS Number

[1447814-75-6]

Product Name Alternative

OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody

UNSPSC

12352203

Target

Notch

Type

Inhibitory Antibodies

Related Pathways

Neuronal Signaling; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/brontictuzumab.html

Purity

95.00

Solubility

10 mM in DMSO

Smiles

[Brontictuzumab]

Molecular Weight

(150 kDa)

References & Citations

[1]Ferrarotto R, et al. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol. 2018 Jul 1;29 (7) :1561-1568. |[2]Silkenstedt E, et al. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy. J Exp Clin Cancer Res. 2019 Nov 1;38 (1) :446. |[3]Agnusdei V, et al. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. Leukemia. 2014 Feb;28 (2) :278-88.